UDC 616.37–002.2–06:616.24–007.272]–036.1–006.327:612.017.1
Introduction. In the case of comorbidity ofchronic pancreatitis (CP) with chronic obstructive pulmonary disease (COPD), chronic systemic inflammation develops, accompanied by increased production of pro-inflammatory cytokines and profibrotic growth factors, promoting the progression of fibrogenesis in both the pancreas and lung tissue.The aim of the study. To investigate the role of pro-inflammatory cytokine production in the development and progression of chronic pancreatitis in patients with chronic obstructive pulmonary disease.Materials and methods. A total of 180 patients were examined and divided into three groups: 60 patients with isolated CP, 60 patients with CP combined with COPD (Group E), and 60 patients with isolated COPD (Group E). Blood levels of TGF-β1, IGF-1, TNF-α, IL-1β, and C-reactive protein (CRP) were assessed, as well as indicators of exocrine pancreatic function.Results.The study results revealed that patients with coexisting CP and COPD demonstrated the most pronounced activation of systemic inflammation and fibrogenesis. Compared with healthy individuals, patients with comorbid CP and COPD had significantly higher TGF-β1 (by 6.2 times), TNF-α (by 5.2 times), IL-1β (by 7.4 times), IGF-1 (by 3.1 times), and CRP (by 21.5 times) levels (p < 0.05), accompanied by more severe exocrine pancreatic insufficiency, reflected by higher symptom scores and lower fecal elastase-1 levels.Conclusions. Comorbid chronic pancreatitis and chronic obstructive pulmonary disease are characterized by excessive production of TGF-β1, IGF-1, TNF-α, and IL-1β, resulting in enhanced systemic inflammation, fibroge-nesis, and pancreatic dysfunction, while direct correlations with inflammatory and exocrine insufficiency markers and inverse correlations with fecal elastase-1 support their role in fibrosis progression.